Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06634719 · ClinicalTrials.gov registry record · NA
Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)
A NA study of Heavy Menstrual Bleeding, sponsored by Rejoni.
- Recruiting
- Registry status
- NA
- Development phase
- 7
- Enrollment target
- 4
- Study locations
NCT06634719: Recruiting NA study of Heavy Menstrual Bleeding, sponsored by Rejoni.
NCT06634719 is a NA study of Heavy Menstrual Bleeding that is actively recruiting participants, run by Rejoni. The registered enrollment target is 7 participants, below the 225-participant average among 9 other Heavy Menstrual Bleeding trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06634719, a NA study of Heavy Menstrual Bleeding, is actively recruiting participants, sponsored by Rejoni.
- RECRUITING
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective, multicenter, single-arm interventional feasibility study to evaluate the safety and feasibility of the Juveena Hydrogel System for temporary control of heavy menstrual bleeding (HMB) in women with a history of chronic ovulatory HMB.
Primary Outcome
Feasibility for invoking a tamponade effect
Conditions Studied
Interventions
- DEVICE Juveena Hydrogel System
Study Locations (4)
Arizona
- Arizona Gynecology Consultants - Phoenix
Arkansas
- Applied Research Center of Arkansas - Little Rock
New Jersey
- Rubino OB/GYN (Axia Women's Health) - West Orange
Ohio
- Seven Hills Clinical Research Group, LLC - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What NCT06634719 shows while recruiting
NCT06634719 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 225-participant average among 9 other Heavy Menstrual Bleeding trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Heavy Menstrual Bleeding appearing as the primary indexed condition, and to 1 intervention - of which Juveena Hydrogel System is the first listed.
NCT06634719 reports a single indexed study location in Arizona, Arkansas, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06634719 about?
NCT06634719 is a clinical study titled "Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)". This is a prospective, multicenter, single-arm interventional feasibility study to evaluate the safety and feasibility of the Juveena Hydrogel System for temporary control of heavy menstrual bleeding (HMB) in women with a history of chronic ovulatory HMB.
What is the current status of trial NCT06634719?
This trial is currently recruiting. It is a NA study. The enrollment target is 7 participants. The study started on 2025-02-01. Estimated completion is 2025-12-31.
What conditions does trial NCT06634719 study?
This clinical trial studies the following conditions: Heavy Menstrual Bleeding.
What interventions are being tested in trial NCT06634719?
The interventions under investigation include: Juveena Hydrogel System (DEVICE).
Who is sponsoring clinical trial NCT06634719?
This trial is sponsored by Rejoni, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06634719 being conducted?
This trial has 4 study locations across Arizona, Arkansas, New Jersey, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heavy Menstrual Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06634719's enrollment target sits among peer trials
7 10th of 9 the lowest of 9 other Heavy Menstrual Bleeding trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heavy Menstrual Bleeding trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease
COMPLETED · NA
-
Transcutaneous Auricular Neurostimulation as a Treatment for Women With Heavy Menstrual Bleeding: A Dose-finding Trial
COMPLETED · NA
-
Minitouch Endometrial Ablation System Treatment for Menorrhagia: An Evaluation of Safety & Effectiveness
COMPLETED · NA
-
Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
RECRUITING
-
A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device
RECRUITING
-
Efficacy and Safety Study of XP12B in Women With Menorrhagia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI